Terms: = Endocrine gland cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4
740 results:
1. Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center.
Neocleous V; Fanis P; Toumba M; Skordis N; Phylactou LA
Orphanet J Rare Dis; 2024 Apr; 19(1):167. PubMed ID: 38637882
[TBL] [Abstract] [Full Text] [Related]
2. [Preparation and characterization of chicken anti-human B7-H4 IgY polyclonal antibody].
Zhang L; Fan Z; Zhang W; Huang H; Wang J; Hei A; Cong Y; Xu J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):257-266. PubMed ID: 38512036
[TBL] [Abstract] [Full Text] [Related]
3. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.
Lin Q; Serratore A; Niu J; Shen S; Roy Chaudhuri T; Ma WW; Qu J; Kandel ES; Straubinger RM
Drug Resist Updat; 2024 Mar; 73():101064. PubMed ID: 38387284
[TBL] [Abstract] [Full Text] [Related]
4. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma.
Cattaneo G; Ventin M; Arya S; Kontos F; Michelakos T; Sekigami Y; Cai L; Villani V; Sabbatino F; Chen F; Sadagopan A; Deshpande V; Moore PA; Ting DT; Bardeesy N; Wang X; Ferrone S; Ferrone CR
Cancer Lett; 2024 Apr; 587():216713. PubMed ID: 38364961
[TBL] [Abstract] [Full Text] [Related]
5. EZH2-mediated development of therapeutic resistance in cancer.
Kaur P; Shankar E; Gupta S
Cancer Lett; 2024 Apr; 586():216706. PubMed ID: 38331087
[TBL] [Abstract] [Full Text] [Related]
6. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
[TBL] [Abstract] [Full Text] [Related]
7. Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
Veneziani AC; Sneha S; Oza AM
Clin Cancer Res; 2024 Apr; 30(8):1434-1437. PubMed ID: 38306232
[TBL] [Abstract] [Full Text] [Related]
8. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.
Bauer N; Balourdas DI; Schneider JR; Zhang X; Berger LM; Berger BT; Schwalm MP; Klopp NA; Siveke JT; Knapp S; Joerger AC
ACS Chem Biol; 2024 Feb; 19(2):266-279. PubMed ID: 38291964
[TBL] [Abstract] [Full Text] [Related]
9. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T; Lin Q; Stachowiak EK; Rosario SR; Spernyak JA; Ma WW; Stachowiak MK; Greene MK; Quinn GP; McDade SS; Clynes M; Scott CJ; Straubinger RM
Clin Cancer Res; 2024 Apr; 30(7):1367-1381. PubMed ID: 38270582
[TBL] [Abstract] [Full Text] [Related]
10. Nanoparticle Targeting in Chemo-Resistant Ovarian cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance.
Wang Y; Calvert AE; Cardenas H; Rink JS; Nahotko D; Qiang W; Ndukwe CE; Chen F; Keathley R; Zhang Y; Cheng JX; Thaxton CS; Matei D
Adv Sci (Weinh); 2024 Apr; 11(13):e2305212. PubMed ID: 38263873
[TBL] [Abstract] [Full Text] [Related]
11. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes.
Zhou Q; Pichlmeier S; Denz AM; Schreiner N; Straub T; Benitz S; Wolff J; Fahr L; Del Socorro Escobar Lopez M; Kleeff J; Mayerle J; Mahajan UM; Regel I
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38240084
[TBL] [Abstract] [Full Text] [Related]
12. Proteomic profiling of ovarian clear cell carcinomas identifies prognostic biomarkers for chemotherapy.
Yue L; Gong T; Jiang W; Qian L; Gong W; Sun Y; Cai X; Xu H; Liu F; Wang H; Li S; Zhu Y; Zheng Z; Wu Q; Guo T
Proteomics; 2024 Mar; 24(6):e2300242. PubMed ID: 38171885
[TBL] [Abstract] [Full Text] [Related]
13. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
14. EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic cancer Progression via Upregulating KLLN.
Yao B; Xing M; Meng S; Li S; Zhou J; Zhang M; Yang C; Qu S; Jin Y; Yuan H; Zen K; Ma C
Adv Sci (Weinh); 2024 Jan; 11(2):e2302037. PubMed ID: 38015024
[TBL] [Abstract] [Full Text] [Related]
15. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract] [Full Text] [Related]
16. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract] [Full Text] [Related]
17. X-linked RBBP7 mutation causes maturation arrest and testicular tumors.
Li J; Zheng H; Hou J; Chen J; Zhang F; Yang X; Jin F; Xi Y
J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37843278
[TBL] [Abstract] [Full Text] [Related]
18. Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer.
Modestino L; Cristinziano L; Poto R; Ventrici A; Trocchia M; Ferrari SM; Fallahi P; Paparo SR; Marone G; Antonelli A; Varricchi G; Galdiero MR
Front Immunol; 2023; 14():1167404. PubMed ID: 37705974
[TBL] [Abstract] [Full Text] [Related]
19. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
20. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers.
Zhang X; Guo H; Chen J; Xu C; Wang L; Ke Y; Gao Y; Zhang B; Zhu J
Cancer Lett; 2023 Sep; 572():216355. PubMed ID: 37597651
[TBL] [Abstract] [Full Text] [Related]
[Next]